Stocktoria

Artiva Biotherapeutics, Inc. ARTV

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-07-19

Artiva Biotherapeutics, Inc. statistics & valuation

Market cap$237.8M
P / B2.2×
Return on equity-76.3%
Return on capital-76.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
-91.60% -26805.60% 202320242025
Return on equity (%)
-35.00% -76.30% 202320242025
Shares outstanding
802747 11.3M 24.4M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-27.30% -31.20% -64.00% 202320242025
Free cash flow margin (%)
-151.30% -22180.90% 202320242025
Debt / equity (×)
202320242025
EPS ($)
-$35.78 -$5.81 -$3.43 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Operating margin—-26805.6%-91.6%
Net margin—-26045.0%-85.8%
FCF margin—-22180.9%-151.3%
Return on assets-64.0%-31.2%-27.3%
Return on equity-76.3%-35.0%17.7%
Current ratio8.6115.396.53

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.